These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26800397)

  • 1. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.
    Zeng LP; Hu ZM; Li K; Xia K
    J Cell Mol Med; 2016 Mar; 20(3):559-67. PubMed ID: 26800397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
    Lei Y; Li B; Tong S; Qi L; Hu X; Cui Y; Li Z; He W; Zu X; Wang Z; Chen M
    PLoS One; 2015; 10(2):e0117809. PubMed ID: 25658842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARĪ³ in esophageal cancer.
    Wu K; Hu Y; Yan K; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
    J Cell Physiol; 2020 Feb; 235(2):1247-1258. PubMed ID: 31267531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
    Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
    Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy.
    Su J; Xu Y; Zhou L; Yu HM; Kang JS; Liu N; Quan CS; Sun LK
    Anat Rec (Hoboken); 2013 Apr; 296(4):595-603. PubMed ID: 23408563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways.
    Noguchi S; Yasui Y; Iwasaki J; Kumazaki M; Yamada N; Naito S; Akao Y
    Cancer Lett; 2013 Jan; 328(2):353-61. PubMed ID: 23104321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.
    Zhou S; Huang Q; Zheng S; Lin K; You J; Zhang X
    Tumour Biol; 2016 May; 37(5):6837-45. PubMed ID: 26662313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
    Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
    Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
    Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer.
    Li Y; Shan Z; Liu C; Yang D; Wu J; Men C; Xu Y
    Biochemistry (Mosc); 2017 Apr; 82(4):474-482. PubMed ID: 28371605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells.
    Liang WL; Cao J; Xu B; Yang P; Shen F; Sun Z; Li WL; Wang Q; Liu F
    Biomed Pharmacother; 2015 May; 72():119-24. PubMed ID: 26054685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR.
    Yu Z; Li N; Jiang K; Zhang N; Yao LL
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5867-5873. PubMed ID: 30280766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer.
    Lin J; Lin Y; Fan L; Kuang W; Zheng L; Wu J; Shang P; Wang Q; Tan J
    Biochem Biophys Res Commun; 2016 Apr; 473(2):382-7. PubMed ID: 26946357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
    Mu DW; Guo HQ; Zhou GB; Li JY; Su B
    Int J Clin Exp Pathol; 2015; 8(11):13864-70. PubMed ID: 26823699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
    Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.